{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:45:28Z","timestamp":1759938328005},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s10072-016-2679-6","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T11:45:40Z","timestamp":1469706340000},"page":"1917-1922","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The economic burden of the care and treatment for people with Alzheimer\u2019s disease: the outlook for the Czech Republic"],"prefix":"10.1007","volume":"37","author":[{"given":"Petra","family":"Mare\u0161ov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Zah\u00e1lkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"2679_CR1","volume-title":"Dementia","author":"V Pidrman","year":"2007","unstructured":"Pidrman V (2007) Dementia. Grada Publishing, Prague"},{"key":"2679_CR2","unstructured":"Alzheimer\u00b4s Disease International (2016) http:\/\/www.alz.co.uk\/ . Accessed 26 April 2016"},{"key":"2679_CR3","unstructured":"Czech Alzheimer Society (CAS) (2015) http:\/\/www.alzheimer.cz\/ . Accessed 26 April 2016"},{"key":"2679_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/00036846.2015.1111986","author":"P Maresova","year":"2015","unstructured":"Maresova P, Mohleska H, Kuca K (2015) Social and family load of Alzheimer\u2019s disease. Appl Econ. doi: 10.1080\/00036846.2015.1111986","journal-title":"Appl Econ"},{"key":"2679_CR5","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2147\/NDT.S87503","volume":"11","author":"H Mohelska","year":"2015","unstructured":"Mohelska H, Maresova P, Valis M, Kuca K (2015) Alzheimer\u2019s disease and its treatment costs: Case Study in the Czech Republic. Neuropsychiatr Dis Treat 11:2349\u20132354. doi: 10.2147\/NDT.S87503","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"2679_CR6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2174\/156720501209151019111448","volume":"12","author":"P Maresova","year":"2015","unstructured":"Maresova P, Mohelska H, Dolejs J, Kuca K (2015) Socio-economic aspects of Alzheimer\u2019s disease. Curr Alzheimer Res 12(9):903\u2013911","journal-title":"Curr Alzheimer Res"},{"key":"2679_CR7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1017\/S1041610206003784","volume":"19","author":"RF Allegri","year":"2007","unstructured":"Allegri RF, Butman J, Arizaga RL et al (2007) Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr 19:705\u2013718","journal-title":"Int Psychogeriatr"},{"key":"2679_CR8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JAD-2008-15109","volume":"15","author":"G Wang","year":"2008","unstructured":"Wang G, Cheng Q, Zhang S et al (2008) Economic impact of de-mentia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimer Dis 15:109\u2013115","journal-title":"J Alzheimer Dis"},{"issue":"4","key":"2679_CR9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/156720510791162430","volume":"7","author":"Mesterton","year":"2010","unstructured":"Mesterton et al (2010) Cross sectional observational study on the societal costs of Alzheimer\u2019s disease. Curr Alzheimer Res 7(4):358\u2013367","journal-title":"Curr Alzheimer Res"},{"key":"2679_CR10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00019053-200119030-00008","volume":"19","author":"HM Lamb","year":"2001","unstructured":"Lamb HM, Goa KL (2001) Rivastigmine. A pharmacoeconomic re-view of its use in Alzheimer\u2019s disease. Pharmacoeconomics 19:303\u2013318","journal-title":"Pharmacoeconomics"},{"key":"2679_CR11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00002512-200421050-00001","volume":"21","author":"A Wimo","year":"2004","unstructured":"Wimo A (2004) Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease: a review with methodologi-cal considerations. Drugs Aging 21:279\u2013295","journal-title":"Drugs Aging"},{"key":"2679_CR12","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/gps.1594","volume":"21","author":"N Herrmann","year":"2006","unstructured":"Herrmann N, Lanct\u00f4t KL, Sambrook R et al (2006) The contribu-tion of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry 21:972\u2013976","journal-title":"Int J Geriatr Psychiatry"},{"key":"2679_CR13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1590\/S1980-57642010DN40400003","volume":"4","author":"D Castro","year":"2010","unstructured":"Castro D, Dillon C, Machnicki G, Allegri R (2010) The economic cost of Alzheimer\u2019s disease: family or public-health burden? Dement Neuropsychol 4:262\u2013267","journal-title":"Dement Neuropsychol"},{"key":"2679_CR14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1377\/hlthaff.12.2.164","volume":"12","author":"DP Rice","year":"1993","unstructured":"Rice DP, Fox PJ, Max W et al (1993) The economic burden of Alzheimer\u2019s disease care. Health Aff (Millwood) 12:164\u2013176","journal-title":"Health Aff (Millwood)"},{"issue":"2015","key":"2679_CR15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jalz.2015.02.005","volume":"11","author":"Dodel","year":"2015","unstructured":"Dodel et al (2015) Determinants of societal costs in Alzheimer\u2019s disease: GERAS study baseline results. Alzheimer\u2019s Dement 11(2015):933\u2013945","journal-title":"Alzheimer\u2019s Dement"},{"issue":"2","key":"2679_CR16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/geront\/43.2.158","volume":"43","author":"Bloom","year":"2003","unstructured":"Bloom et al (2003) Cost of illness of Alzheimer\u2019s disease: How useful are current estimates? The Gerontologist 43(2):158\u2013164","journal-title":"The Gerontologist"},{"key":"2679_CR17","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, O\u00b4Brien BJ (2005) Methods for the economic evaluation of health care programmes. Oxford University, New York"},{"key":"2679_CR18","unstructured":"The State Institute for Drug Control (SUKL) (2012). Evaluation of the development of distribution selected group of medicines. State Institute for Drug Control. http:\/\/www.sukl.cz\/hodnoceni-vyvoje-distribuce-vybrane-skupiny-lecivych-9 . Accessed 26 April 2016"},{"key":"2679_CR19","unstructured":"Czech Statisical Office (CSO) (2014) Ageing population according to the results of the CSO projection. http:\/\/www.demografie.info\/?cz_detail_clanku&artclID . Accessed 26 April 2016"},{"issue":"1","key":"2679_CR20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.healthpol.2014.01.001","volume":"116","author":"Ch Gerv\u00e8s","year":"2014","unstructured":"Gerv\u00e8s Ch, Chauvin P, Bellanger MM (2014) Evaluation of full costs of care for patients with Alzheimer\u2019s disease in France: the predominant role of informal care. Health Policy 116(1):114\u2013122","journal-title":"Health Policy"},{"issue":"6","key":"2679_CR21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jval.2011.04.005","volume":"14","author":"L Schwarzkopf","year":"2011","unstructured":"Schwarzkopf L, Menn P, Kunz S et al (2011) Costs of care for dementia patients in community setting: an analysis for mild and moderate disease stage. Value Health 14(6):827\u2013835. doi: 10.1016\/j.jval.2011.04.005","journal-title":"Value Health"},{"key":"2679_CR22","unstructured":"Travnickova J(2013). Economics and management in health care: 3rd edition of Proceedings of the student scientific conference organized by the Department of Biomedical Technology: Kladno, p 205\u2013212"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-016-2679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-016-2679-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-016-2679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T10:57:20Z","timestamp":1718708240000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-016-2679-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2679"],"URL":"https:\/\/doi.org\/10.1007\/s10072-016-2679-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}